Screening study for people at high risk for pancreatic cancer
CAPS5 is a study looking at screening for early cancer in people with an elevated lifetime risk of developing pancreatic cancer. The goal is to study biomarkers derived from images and tissue samples (blood, pancreas fluid, duodenal fluid) for the early detection of pancreatic cancer and precancerous lesions.
Screening for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk.
The purpose of this study is to try to find markers of early pancreatic cancer for screening for individuals at higher-than-average risk, expedite the diagnosis in individuals with symptoms, and substantially improve an individual's chance of surviving the disease.
Improved screening for pancreatic cancer in high-risk groups, such as people with an inherited BRCA1, BRCA2, ATM, or PALB2 mutation, may help find cancer early and improve survival rates. People enrolled in this study will undergo screening using endoscopic ultrasound or MRI of the abdomen.
The Ohio State University and FORCE want to understand if a family communication guide for people with BRCA mutations is helpful and if it’s also useful to have a video that you can text or email to family members that explains your BRCA mutation. We are currently looking for people between the ages of 18-80 who have mutation in BRCA1 or BRCA2, have an active email address, and an internet capable device like a computer, tablet, or smartphone. Participants will be asked to complete a total of 3 surveys. Participants will be randomly assigned to either receive just the communication guide or the guide plus the sharable. Each survey will take 10-15 minutes (the study could take up to 1.5 hours to complete depending on how much time you spend reviewing the study materials).
You can get more information or ask to participate in the study by sending an email to: [email protected].
The purpose of this study is to screen and detect pancreatic cancer and precancer in people with either a strong family history of pancreatic cancer, or an inherited mutation associated with pancreatic cancer risk.
Magnetic Resonance Imaging (MRI) will be used to screen for early stage pancreatic cancer. Participants will also be asked to donate a blood sample at specific intervals for the creation of a blood bank necessary for the development of a blood-based screening test for pancreatic cancer.
This is a study looking at esophageal ultrasound and Magnetic Resonance Imaging (MRI) as a screening for pancreatic cancer in high risk individuals.
Additional Results on Clinicaltrials.gov Prevention, Detection & Risk + Pancreatic Cancer + Screening & Early Detection
A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals
NCT ID: NCT03250078 (https://classic.clinicaltrials.gov/show/NCT03250078)
Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk
NCT ID: NCT02478892 (https://classic.clinicaltrials.gov/show/NCT02478892)
A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus
NCT ID: NCT03937453 (https://classic.clinicaltrials.gov/show/NCT03937453)
Blood Markers of Early Pancreas Cancer
NCT ID: NCT03568630 (https://classic.clinicaltrials.gov/show/NCT03568630)
New Onset Diabetes Management for Earlier Detection of Pancreatic Cancer (NODMED)
NCT ID: NCT05188586 (https://classic.clinicaltrials.gov/show/NCT05188586)
Pancreatic Cancer Early Detection Program
NCT ID: NCT02206360 (https://classic.clinicaltrials.gov/show/NCT02206360)
DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)
NCT ID: NCT04825834 (https://classic.clinicaltrials.gov/show/NCT04825834)
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.